Previous 10 | Next 10 |
Halozyme Raises Full Year 2020 Guidance - Raises 2020 Guidance to $265 Million to $275 Million in Revenues, Up from $250 Million to $260 Million, and EPS of $0.90 to $0.95, Up from $0.80 to $0.85 - PR Newswire SAN DIEGO, Nov. 23, 2020 SAN DIEGO , Nov. 23, 2...
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology - Horizon to use ENHANZE® subcutaneous delivery technology for TEPEZZA® (teprotumumab-trbw) - PR Newswire DUBLIN and SAN DIEGO...
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference PR Newswire SAN DIEGO, Nov. 18, 2020 SAN DIEGO , Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen...
Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer - Phesgo® Can be Administered in 5 t...
Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multipl...
Palm Beach, FL –November 9, 2020 – Much time and money has been allocated in the global breast cancer drug market, and multiple reports project continued growth in the sector. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends sto...
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&...
Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. ...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q3 2020 Earnings Call Nov 2, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics Inc (HALO) Q3 2020 Earnings Call Transcript ...
Halozyme Therapeutics, Inc. (HALO) Q3 2020 Results Earnings Conference Call November 02, 2020, 04:30 PM ET Company Participants Al Kildani - Vice President-Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Elaine Sun - Chief Financial Officer...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...